OncoMatch/Clinical Trials/NCT07101705
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Is NCT07101705 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies OriV508 for multiple myeloma (mm).
Treatment: OriV508 — This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-CD20 monoclonal antibody
Previous treatments must include standard treatment regimens with anti-CD20 monoclonal antibodies (except for subjects with CD20-negative tumors)
Must have received: anthracycline
Previous treatments must include standard treatment regimens with...anthracyclines
Cannot have received: autologous hematopoietic stem cell transplantation
Received autologous hematopoietic stem cell transplantation within 24 weeks prior to signing the ICF
Cannot have received: allogeneic hematopoietic stem cell transplantation
Received organ transplantation or allogeneic hematopoietic stem cell transplantation
Cannot have received: small molecule targeted therapy
Small molecule targeted therapy...within 14 days or at least 5 half-lives, whichever is longer
Cannot have received: epigenetic therapy
epigenetic therapy...within 14 days or at least 5 half-lives, whichever is longer
Cannot have received: investigational drug
treatment with an investigational drug or used an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer
Cannot have received: immunosuppressive agent (tacrolimus, mycophenolate mofetil)
Immunosuppressive agent therapy (such as tacrolimus, mycophenolate mofetil, etc.) within 28 days
Cannot have received: monoclonal antibody
Monoclonal antibody treatment within 21 days
Cannot have received: cytotoxic chemotherapy
Cytotoxic therapy within 14 days
Cannot have received: proteasome inhibitor
Proteasome inhibitor therapy within 14 days
Cannot have received: immunomodulator
Immunomodulator agent therapy within 7 days
Cannot have received: corticosteroid (prednisone)
Exception: physiological replacement dose, topical and inhaled corticosteroids are permitted
Therapeutic dose of corticosteroids (defined as prednisone ≥ 20 mg/day or equivalent dose of other corticosteroids) within 72 hours
Cannot have received: radiation therapy
Exception: only for subjects whose radiation field covers > 5% of bone marrow reserve
Radiotherapy within 28 days (only for subjects whose radiation field covers > 5% of bone marrow reserve)
Cannot have received: viral therapy using vesicular stomatitis virus G (VSVG)-pseudotyped virus
Previously treated with any viral therapy using vesicular stomatitis virus G (VSVG)-pseudotyped virus
Lab requirements
Blood counts
Hemoglobin ≥ 6 g/dL (no RBC transfusion within 1 week prior to screening, recombinant human erythropoietin permitted); ANC ≥ 750 /μL (no G-CSF within 1 week or no pegylated G-CSF within 2 weeks prior to screening); Platelet count ≥ 50,000 /μL; Lymphocyte count ≥ 500 /μL
Kidney function
Creatinine clearance (CrCl) (MDRD formula) ≥ 40 mL/min/1.73m² (for MM subjects with CrCl < 40 mL/min/1.73m², investigator discretion)
Liver function
ALT and AST ≤ 3.0 × ULN, total bilirubin ≤ 1.5 × ULN (for subjects with Gilbert's syndrome or liver invasion by tumor, ALT and AST ≤ 5.0 × ULN and total bilirubin ≤ 3 × ULN are permitted)
Cardiac function
Left ventricular ejection fraction ≥ 45%
Hemogram meets the following requirements...Renal function...Liver function...Cardiac function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07101705 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplantation, allogeneic hematopoietic stem cell transplantation, small molecule targeted therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages